AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of “Moderate Buy” by Analysts
Shares of AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month […]
More Stories
The Great Banking Betrayal: Who Really Paid the Price?
By Stephen Zogopoulos, USNN World News USNN WORLD NEWS | SPECIAL EDITORIAL INVESTIGATION October 30, 2026 | Investigative Opinion &...
Trump Says Democratic Candidate Should Be Prosecuted Amid Alaska Same-Name Controversy
By Jack Phillips President Donald Trump has called for the prosecution of a Democratic Alaska Senate candidate amid allegations that...
Greenville Police Rule Hayden Panettiere’s Death Accidental, Close Investigation
By Kimberly Hayek The Greenville, South Carolina, police department concluded its investigation Wednesday into the death of actress Hayden Panettiere...
Acclaimed Stage Actor Patrick Stewart, and ‘Star Trek’ and ‘X-Men’ Star, Dies at Age 86
By Elma Aksalic British actor Sir Patrick Stewart, best known for his roles in the “Star Trek” franchise and “X-Men”...
Judge Narrows Defamation Lawsuit Against Candace Owens Over Claims Brigitte Macron Is Male
By Rachel Roberts A Delaware judge ruled that French President Emmanuel Macron and his wife, Brigitte, can continue their defamation...
Supreme Court Declines to Restore Biden-era Immigration Regulation
By Zachary Stieber The Supreme Court on Oct. 27 allowed an immigration agreement between Texas and the Department of Justice...